BDP/FF/GB single-inhaler triple therapy in COPD: real-world effectiveness, safety, and adherence in a pooled analysis of 5,000 patients - PubMed
4 hours ago
- #COPD
- #Real-world Study
- #Triple Therapy
- BDP/FF/GB single-inhaler triple therapy (SITT) was evaluated in a real-world study of 5,000 COPD patients.
- Significant improvements in health-related quality of life (HRQoL) were observed, with mean CAT score reductions of -3.8 and -4.7 at months 3 and 6.
- Patients with at least one exacerbation decreased from 93.1% pre-treatment to 35.7% at 12 months.
- FEV1 improvements were noted, with over 40% of patients achieving ≥100 mL increase.
- Adherence to therapy significantly improved, with poor-adherence patients transitioning to higher adherence categories.
- Predictors of treatment response included poor baseline adherence, ex-smokers, and experiencing two exacerbations (vs. >2).
- Adverse events were reported by 21.9% of patients.
- The study concluded that BDP/FF/GB SITT is effective and safe in improving symptoms, lung function, and adherence in COPD patients.